Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine followed by donor lymphocyte infusion for relapsed AML/MDS after allo-SCT
2012-005535-90Phase 2Completed
- Sponsor
- CHU UCL Namur - Site Mont-Godinne
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Relapse of disease after allogeneic hematopoietic stem cell transplantation, sponsored by CHU UCL Namur - Site Mont-Godinne. Started Jun 2013; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Relapse of disease after allogeneic hematopoietic stem cell transplantation
Beyond the preview
Go deeper on 2012-005535-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005535-90.